DailyIQ
DailyIQ
Last updatedUpdating…

THC·Tenet Healthcare Corporation

$293.33
+26.64 (+9.99%)
High
$293.78
Open
$280.00
Market Cap
21.82B
52W High
$284.60
Low
$267.00
P. Close
$293.33
P/E
9.74
52W Low
$157.58
Fwd P/E
13.04
DailyIQ Est.
$311.88
Inst. Own.
82.2%
Short Interest
2.45%
Days to Cover
3.3
NewEarnings release, scored · filed Oct 29, 2026tone -9.2 vs prior release · 114 lines scoredSee the breakdown
Technical Score (1D)
71
BULLISH
News Sentiment
59
BULLISH
On Nov 4, Tenet Healthcare Corporation (THC) was highlighted as a trending stock on Zacks, reflecting growing investor interest. The article noted that THC had outperformed the S&P 500 by 3.2% in the last month, while the broader medical‑hospital sector gained 2.3%. Zacks attributed the upside to favorable earnings estimate revisions by sell‑side analysts, suggesting a positive outlook for the company’s future earnings stream. The piece emphasized that fundamental factors, rather than rumors, were driving the buy‑and‑hold decision for THC. No other developments were reported for the company on that date.
LOW TARGET
$265 -9.7%
2 analysts
MEAN TARGET
$304 +3.7%
14 analysts
HIGH TARGET
$342 +16.6%
14 analysts
PRICE RANGE
$265.00 - $342.00
SB / B / H / S / SS
6/17/5/1/1
DAILYIQ EST.
$311.88 (+6.3%)
Sector
Healthcare
Industry
Medical Care Facilities
Exchange
NYQ
Country
United States
Symbol
THC
Description
Tenet Healthcare Corporation is a U.S.-based healthcare services provider operating through two primary segments: Hospital Operations and Services, and Ambulatory Care. The company's core value proposition lies in its comprehensive network of acute care hospitals, offering a wide array of services including surgery, radiology, and specialized treatments for various conditions. These hospitals also provide intensive care, specialized surgical procedures, and tertiary care services. Furthermore, Tenet expands its reach through ambulatory surgery centers, urgent care facilities, and imaging centers, providing convenient access to outpatient care. Founded in 1967, the company's diversified service offerings and extensive physical footprint are key elements of its competitive positioning within the healthcare landscape.
Bought (1Y)
0 shares
$0
Sold (1Y)
194,837 shares
$51.5M
KERREY J ROBERT-
Sell2,502 shares2026-09-14
KERREY J ROBERT-
Sell4,025 shares2026-09-14
KERREY J ROBERT-
Sell5,483 shares2026-09-14
MARK RICHARD J-
Sell10,000 shares2026-09-10
West Nadja-
Sell1,152 shares2026-09-02
62/ 100
Neutral / mixed
Overall: Neutral
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Net Margin
3.6%
Revenue CAGR
5.5%
Current Ratio
1.76x
Debt / Equity
3.10x
Return on Equity
18.2%
Earnings Summary
In the most recent quarters, Tenet posted EPS of $6.12 in Q2 2026 and $6.64 in Q3 2026, both well above analyst expectations of $4.26 and $4.67 respectively, while revenue grew from $5.628 billion to $5.631 billion, matching or slightly exceeding forecasts of $5.511 billion and $5.571 billion; the company consistently beat earnings estimates in the last four quarters. Historically, Tenet has shown a steady YoY revenue expansion, with EPS growth outpacing revenue in the same periods, and has maintained a pattern of earnings beats even when revenue growth decelerated slightly, underscoring disciplined cost control. Recent news highlights include RBC’s price target lift to $304 on November 2, driven by confidence in Tenet’s earnings trajectory, and the company’s own guidance upgrade in early November citing higher‑acuity surgeries and tighter cost control; these developments reinforce the narrative of operational strength. The focus will be on any changes in margin dynamics or cost‑control initiatives that could impact the company’s profitability outlook.

EPS

EstBeatMiss
$2.26$3.50$4.74$5.97$7.21Q4'24Q4'25Q2'26Q3'26Q4'26
QtrEstActual+/−
Q4'26$5.50 - -
Q3'26$4.67$6.64+42.3%
Q2'26$4.26$6.12+43.5%
Q4'25$4.09$4.70+14.8%
Q4'24$2.83$3.44+21.5%

Revenue

EstBeatMiss
$5.0B$5.2B$5.4B$5.6B$5.8BQ4'24Q4'25Q2'26Q3'26Q4'26
QtrEstActual+/−
Q4'26$5.7B - -
Q3'26$5.6B$5.6B+1.1%
Q2'26$5.5B$5.6B+2.1%
Q4'25$5.5B$5.5B+0.0%
Q4'24 - $5.1B -

Market Data

THC Stock Snapshot

BULLISH71/100
$293.33+$26.64 (10.0%)
Market cap
21.82B
P/E ratio
9.7
Day range
$267.00 – $293.78
News sentiment
59/100 · Neutral
Analyst target
$304.14 (+3.7%)
Consensus
Buy · 30 analysts
52-week range+86.1% off low · +3.1% from high
$157.58$284.60
Price $293.33 DailyIQ Est. $311.88

The signal on THC is bullish: price action is confirming the underlying trend, not fighting it. The stock is liquid enough that positioning changes get absorbed without distorting the trend.

Reverse DCF

What growth is priced into THC?

CHEAP

At today's price, Tenet Healthcare Corporation needs to grow free cash flow about -1.7% a year for 3 years, slowing to a long-run rate by year 10, to justify its valuation at a 7.02% cost of capital. Over the last five years its revenue has trended at 2.6% a year, so the market is asking for 4.3 percentage points below its own delivered rate. On that basis THC looks priced below what its own growth record supports.

Implied FCF growth
-1.7%
Growth trend
2.6%
Growth gap
-4.3 pts
Verdict
CHEAP
Discount rate (WACC)
7.02%
Beta
0.76

Behaviour On Record

What THC's own history says about today's numbers

Realized volatility (21d)
23.9% 5th pct
Below its peak
-1.1%
vs 200-day average
+25.0%
Up days (1y)
49%

Tenet Healthcare Corporation is currently running 23.9% annualised volatility over the last 21 sessions. Measured against THC's own 13 years of daily returns rather than a market-wide average, that is the 5th percentile — unusually subdued by its own history, against a typical reading of 43.2%.

THC is trading -1.1% below its running peak. Across 13 full years on file, its median worst-drawdown-in-a-year was -45.0%, and the deepest was -71.7% in 2020. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits +25.0% from its 200-day moving average. Against every other day in its history, that gap ranks at the 75th percentile — a somewhat wider gap than its own norm. Over the past year THC closed higher on 49% of sessions, and it is currently 1 session into a rising streak.

On November specifically: over 13 years of records, THC finished the month higher 8 of 13 times, with a median return of +1.9% and an average of +3.2%. Its strongest month historically has been July at +10.9% on average, its weakest September at -6.7%.

Overnight risk is measurable too: THC has opened more than 2% away from the prior close in 288 of 3,268 sessions (8.8% of the time), with the largest gaps running +11.0% and -12.7%.

Across the last 3 dated reports on file, THC moved an average of 2.9% in the session after earnings, closing higher 3 of those 3 times, with a median move of +2.8% and a largest of +4.1%.

All figures computed from 3,269 daily closes between 2013-11-05 and 2026-11-04, split-adjusted, recomputed daily. Percentiles are against THC's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of THC's sector?

Tenet Healthcare Corporation sits in the Health Care sector, currently ranked 1st of 12 GICS sectors by relative-strength rotation score (leading).

Sector rank
#1 of 12
Sector state
Leading
Sector rotation score
91

Options Market

What is the options market pricing for THC?

CallsPuts

For Tenet Healthcare Corporation's nearest expiry (2026-11-20, 16 days out), open interest is roughly balanced between puts and calls (put/call ratio of 0.89), with at-the-money implied volatility around 41.7%. The options market is pricing roughly a ±9.2% move by that expiry — a range of about $263.63–$317.37.

Put/call ratio (2026-11-20)
0.89
ATM implied volatility
41.7%
Total open interest
6,907
Expected move by 2026-11-20
±9.2% ($263.63–$317.37)

Analyst Consensus Estimates

What do analysts expect THC to earn?

Analysts expect Tenet Healthcare Corporation to earn $22.17 per share in the fiscal year ending Dec 2026 and $22.51 in the fiscal year ending Dec 2028, from 5 estimates. These are analyst forecasts, not company guidance, and later years rest on fewer analysts.

Quarter endingEPS estimateEPS rangeEPS analystsRevenue estimateRevenue analysts
Dec 2026$5.41$4.47 to $6.0919$5.69B18
Mar 2027$4.64$3.85 to $5.3812$5.45B9
Jun 2027$5.14$4.66 to $5.954~$5.61B-
Sep 2027$4.91$4.50 to $5.474~$5.36B-
Fiscal year endingEPS estimateEPS rangeEPS analystsRevenue estimateRevenue analysts
Dec 2026$22.17$21.05 to $23.0120$22.46B21
Dec 2027$20.52$17.92 to $23.2120$22.52B20
Dec 2028$22.51$20.09 to $25.115~$24.57B-

Revenue marked ~ is our calculation from the EPS estimate, not analyst consensus.

Analyst Rating Changes

Are analysts turning bullish or bearish on THC?

Truist Securities most recently reiterated its rating on Tenet Healthcare Corporation to Buy on Nov 3, 2026 with a price target of $305 (from $290). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
Truist Securities: Buy
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Nov 3, 2026Truist SecuritiesReiteratedBuy$290 → $305
Nov 3, 2026KeybancMaintainedOverweight$270 → $300
Nov 2, 2026Leerink PartnersMaintainedOutperform$309 → $342
Nov 2, 2026RBC CapitalMaintainedOutperform$283 → $304
Nov 2, 2026Wells FargoMaintainedOverweight$281 → $321
Oct 30, 2026GuggenheimMaintainedBuy$307 → $306
Oct 16, 2026GuggenheimMaintainedBuy$283 → $307
Sep 23, 2026BMO CapitalInitiatedMarket Perform$265
Sep 18, 2026Leerink PartnersMaintainedOutperform$309
Aug 3, 2026Wells FargoMaintainedOverweight$231 → $281
Jul 28, 2026Truist SecuritiesMaintainedBuy$270 → $290
Jul 28, 2026BairdMaintainedNeutral$210 → $280

Earnings Release, Scored

What did Tenet Healthcare Corporation's latest earnings release say?

Filed Oct 29, 2026 · SEC Form 8-K, Exhibit 99

Tone63.4/ 100-9.2 vs prior release
Hedging words0.25per 100 words+0.01 vs prior release
Tone, last 3 releasesScale 50–78

Most important lines

  1. 1

    Results also include the $147 million favorable net impact described above.

    New this quarter
  2. 2

    Results also include the net favorable impact of $147 million from transition activities described on page 2.

    New this quarter
  3. 3

    As a result of this revised timeline, during the three months ended September 30, 2026, we recognized cumulative catch-up adjustments that increased revenue from contract termination by $233 million and net operating revenues by $97 million.

    New this quarter

Peers & ETF holders

THC peers & ETF holders

News & sentiment

What is the news saying about THC?

THC rose 13.4% over the month to Nov 4. News tone held between 58 and 79 from Oct 2 to Oct 16, then dropped to 43 on Oct 19.

Daily close and news tone, Oct 2 to Nov 4
$260$280Oct 2: tone 60Oct 5: tone 59Oct 6: tone 79Oct 7Oct 8: tone 62Oct 9: tone 64Oct 12Oct 13Oct 14Oct 15: tone 64Oct 16: tone 72Oct 19: tone 43Oct 20: tone 42Oct 21: tone 65Oct 22: tone 76Oct 23Oct 26: tone 54Oct 27: tone 63Oct 28: tone 35Oct 29: tone 61Oct 30: tone 66Nov 2: tone 65Nov 3: tone 51Nov 4: tone 60Oct 2News toneNov 4123
  1. Oct 16 -2.9%same day: Tenet Healthcare’s Rally Raises a Key Question About Its Valuation
  2. Oct 20 +2.2%same day: Tenet Fintech: Turning SME Data Into Business Opportunities With AI
  3. Nov 4 +10.0%same day: Tenet Healthcare Corporation (THC) Is a Trending Stock: Facts to Know Before Betting on It

Technical analysis

How strong is THC's momentum right now?

On the daily chart THC ranks at the 71st percentile for momentum against 1,060 stocks and ETFs, a bullish reading.

Momentum rank by timeframe0 = weakest, 100 = strongest
See what drives the rankThe inputs behind each timeframe's momentum rank, plus RSI, stochastics, Bollinger Bands and moving averages. Free with an account.

Institutional ownership

Are big funds buying or selling THC?

82 of the 175 tracked managers added to THC in their latest 13F and 86 trimmed. Together they own 82.2% of the company, worth $11.5B. BlackRock and Boston Partners alone hold 17.6%.

82adding86trimming7unchanged
Largest holders by stake, latest 13FBar = share of THC
  1. $1.6B positionAdded 0.4% last quarter
  2. $829.1M positionAdded 15.6% last quarter
  3. $792.9M positionTrimmed 1.8% last quarter
  4. $747.3M positionTrimmed 48.6% last quarter
  5. $728.5M positionTrimmed 0.4% last quarter
  6. $514.7M positionAdded 1.3% last quarter
  7. $418.2M positionAdded 46.6% last quarter
  8. $352.7M positionTrimmed 2.4% last quarter
  9. $330.3M positionAdded 321.6% last quarter
  10. $319.6M positionAdded 154.3% last quarter
Full holdings history

Congressional trading

Is Congress trading THC?

2 members of Congress disclosed 7 THC trades between Jun 11, 2025 and Apr 20, 2026: 3 buys and 4 sells, about $105.0K in estimated value.

BuysSellsJulSepNovJan ’26Mar
BuySell$1K–$15K$15K–$50K$50K–$100K$100K–$250K

What stands out

Click one to highlight its trades in the chart

Discover more

How has THC done against its peers?

Over the six months to Nov 4, THC returned +58.3%. Of the 15 related stocks and ETFs, none did better.

Change since May 4, through Nov 4
−50%−25%0%+25%+50%+75%May 4JunJulAugSepOctNov 4THC +58.3%AZN +4.0%